AbbVie's ABBV-466 shows higher remission rates in Crohn's trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to AbbVie's ABBV-466 shows higher remission rates in Crohn's trial

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Diseas

October 19, 2026 4:00 AM EDT

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-47 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 241 Gene expression analysis showed that ABBV-466 treated Crohn's disease patients experienced intestinal tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes reported at Week 241 The results will be presented as a late-breaker at the 2026 Annual United European Gastroenterology Week Congress... More